Layton D - Search Results

1

Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.

Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA. Layton D, et al. Drug Saf. 2006;29(8):687-96. doi: 10.2165/00002018-200629080-00005. Drug Saf. 2006. PMID: 16872242

2

Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.

Shakir SA, Wilton LV, Boshier A, Layton D, Heeley E. Shakir SA, et al. Among authors: layton d. BMJ. 2001 Mar 17;322(7287):651-2. doi: 10.1136/bmj.322.7287.651. BMJ. 2001. PMID: 11250850 Free PMC article. No abstract available.

3

Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.

Layton D, Clark DW, Pearce GL, Shakir SA. Layton D, et al. Eur J Clin Pharmacol. 2001 May;57(2):167-76. doi: 10.1007/s002280100263. Eur J Clin Pharmacol. 2001. PMID: 11417450

4

Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.

Layton D, Pearce GL, Shakir SA. Layton D, et al. Drug Saf. 2001;24(9):703-13. doi: 10.2165/00002018-200124090-00005. Drug Saf. 2001. PMID: 11522122

5

Monitoring the safety of over the counter drugs. We need a better way than spontaneous reports.

Clark D, Layton D, Shakir SA. Clark D, et al. Among authors: layton d. BMJ. 2001 Sep 29;323(7315):706-7. doi: 10.1136/bmj.323.7315.706. BMJ. 2001. PMID: 11576964 Free PMC article. No abstract available.

6

Prescription-event monitoring and reporting of adverse drug reactions.

Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Heeley E, et al. Among authors: layton d. Lancet. 2001 Dec 1;358(9296):1872-3. doi: 10.1016/S0140-6736(01)06898-2. Lancet. 2001. PMID: 11741629

7

Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.

Clark DW, Layton D, Wilton LV, Pearce GL, Shakir SA. Clark DW, et al. Among authors: layton d. Drug Saf. 2001;24(15):1143-54. doi: 10.2165/00002018-200124150-00005. Drug Saf. 2001. PMID: 11772147

8

Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.

Key C, Layton D, Shakir SA. Key C, et al. Among authors: layton d. Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):143-8. doi: 10.1002/pds.690. Pharmacoepidemiol Drug Saf. 2002. PMID: 11998539

9

Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.

Shakir SA, Layton D. Shakir SA, et al. Among authors: layton d. Drug Saf. 2002;25(6):467-71. doi: 10.2165/00002018-200225060-00012. Drug Saf. 2002. PMID: 12071785

10

Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK.

Layton D, Sinclair HK, Bond CM, Hannaford PC, Shakir SA. Layton D, et al. Pharmacoepidemiol Drug Saf. 2002 Sep;11(6):503-13. doi: 10.1002/pds.734. Pharmacoepidemiol Drug Saf. 2002. PMID: 12426936

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters